Alcohol Addiction Clinical Trial
Official title:
Quantitative Analysis of the Expression of Dementia-relevant Genes by Intake of the Drug Disulfiram
A causal therapeutic approach for treatment of Alzheimer's disease has not been established so far. The protein ADAM10 represents a promising target for an A-beta peptide preventing strategy. Treatment of human neuronal cells with Disulfiram, a drug which is used in clinical routine for recrudescence prevention of alcohol dependency, revealed an increased expression of ADAM10. This finding indicates a neuroprotective potential of Disulfiram. The investigators' research purpose aims at the verification of the results obtained in cell culture experiments in the human organism. Therefore, include alcohol addicted patients were included, which take the drug Disulfiram for recrudescence prevention, in our study. Patients are recruited from the patient-collective of the University Medical Center Mainz and the Central Institute for Mental Health Mannheim. Blood samples (max. 5 ml) are taken from the participants before the intake of Disulfiram and about two weeks after treatment. Demographic data are collected (such as age or onset of addiction). Gene expression is analyzed via reverse transcription polymerase chain reaction(RT-PCR) from blood cell-derived messenger ribonucleic acid (mRNA).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04336293 -
sTMS for Substance Use-disordered Veterans
|
N/A | |
Recruiting |
NCT01934751 -
Effectiveness of a Hospital Addiction Service in Treating Opioid and Alcohol Addiction
|
N/A | |
Recruiting |
NCT03589118 -
Qi Gong as a Method of Craving Reduction in Severe Addict Patients
|
N/A | |
Terminated |
NCT02374905 -
Testing Interventions to Reduce Alcohol Consumption Among Outpatients in a Dental Setting
|
N/A | |
Recruiting |
NCT02643264 -
Repetitive Transcranial Magnetic Stimulation (rTMS) of the Insula for Treatment of Alcohol Addiction
|
N/A | |
Not yet recruiting |
NCT01973127 -
Transcranial Magnetic Stimulation in the Treatment of Addiction
|
N/A | |
Recruiting |
NCT05895643 -
Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?
|
Phase 2 | |
Recruiting |
NCT03018236 -
Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.
|
Phase 4 | |
Terminated |
NCT02014779 -
Internet-Based Relapse Prevention vs Face to Face Therapy at an Employee Assistance Program
|
N/A | |
Completed |
NCT02384304 -
Guided and Unguided Internet Treatment for Problematic Alcohol Use
|
N/A | |
Completed |
NCT05093296 -
Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder
|
Phase 2/Phase 3 | |
Terminated |
NCT03854942 -
Study of the Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System
|
Phase 1 | |
Terminated |
NCT03190356 -
Soberlink - MAP Outcomes Study Protocol
|